Showing results (121-130 of 140) with videos related to
Sort By:
Pageof 14
Emerging Microbes & Infections|May 5, 2026
A copper uptake ABC transport system is essential for Mycobacterium tuberculosis virulenceZhihong Xu, Huang Tang, Meiyi Yan, et al.Frontiers in Immunology|June 24, 2025
Insights into immune-related adverse events in colorectal cancer patients receiving neoadjuvant immunotherapy: findings from a multicenter registry studyChentong Wang, Quan Wang, Jiaolin Zhou, et al.Liver Cancer|June 23, 2025
Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular CarcinomaXinyu Bi, Yinying Lu, Bo Chen, et al.Journal for Immunotherapy of Cancer|June 21, 2020
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 studyLin Shen, Jun Guo, Qingyuan Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2023
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical TrialsXinan Sheng, Lin Wang, Zhisong He, et al.Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.Cancer Research and Treatment|February 16, 2021
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II StudyHongzhe Shi, Wen Zhang, Xingang Bi, et al.Annals of Translational Medicine|April 3, 2023
Nomogram for tumour response based on prospective cohorts of hepatocellular carcinoma patients receiving immunotherapy combined with targeted therapy: development and validationQichen Chen, Yiqiao Deng, Chuanhua Zhao, et al.BMC Medicine|March 7, 2023
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCCYong Li, Aiping Zhou, Shuoyan Liu, et al.Cancer Communications (London, England)|December 31, 2024
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 updateFeng Wang, Gong Chen, Zhen Zhang, et al.Pageof 14